BLOG

Fierce-Biotech

Inhalable anti-COVID-19 antibody from TFF and Augmenta tamps down viral load in hamsters

When startup TFF Pharmaceuticals raised $14 million in a series A in 2018, its intention was to deploy its dry-powder drug-delivery technology toward making novel inhalable therapies for asthma, chronic obstructive pulmonary disease and other serious lung diseases. Then COVID-19 hit, and the company saw an opportunity to apply the platform to the emerging virus.